Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

The ALK tyrosine kinase inhibitor (TKI), crizotinib, shows significant activity in patients whose lung cancers harbor ALK fusions but its efficacy is limited by variable primary responses and acquired resistance. In work arising from the intriguing clinical observation of a patient with ALK fusion+...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Lovly, Christine M., McDonald, Nerina T., Chen, Heidi, Ortiz-Cuaran, Sandra, Heukamp, Lukas C., Yan, Yingjun, Florin, Alexandra, Ozretić, Luka, Lim, Diana, Wang, Lu, Chen, Zhao, Chen, Xi, Lu, Pengcheng, Paik, Paul K., Shen, Ronglai, Jin, Hailing, Buettner, Reinhard, Ansén, Sascha, Perner, Sven, Brockmann, Michael, Bos, Marc, Wolf, Jürgen, Gardizi, Masyar, Wright, Gavin M., Solomon, Benjamin, Russell, Prudence A., Rogers, Toni-Maree, Suehara, Yoshiyuki, Red-Brewer, Monica, Tieu, Rudy, de Stanchina, Elisa, Wang, Qingguo, Zhao, Zhongming, Johnson, David H., Horn, Leora, Wong, Kwok-Kin, Thomas, Roman K., Ladanyi, Marc, Pao, William
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2014
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4159407/
https://ncbi.nlm.nih.gov/pubmed/25173427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3667
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg